UCB (UCB) Company Presentation summary

Strategic vision and legacy

• Patient Value Strategy (PVS) has guided innovation since 2015, focusing on patient-centered solutions and measurable impact.

• Achieved 25 approvals and launches in key regions over the last 24 months, reflecting strong R&D productivity and global reach.

• Strategy emphasizes elevating lives through medicines, targeting disease modification and potential cures.

• Culture prioritizes well-being, social responsibility, and health equity through partnerships.

• Commitment to delivering value extends to patients, shareholders, employees, and the planet.

Financial performance and growth

• Projected 2024 revenue of ~€6bn, with EBITDA margins at the upper end of 23.0% to 24.5%.

• Annual revenue grew 50% from €3.9bn in 2015 to €6bn projected for 2024.

• Adjusted EBITDA increased 75% from €0.8bn to €1.4bn over the same period.

• Market capitalization tripled from €12bn in 2015 to €37bn projected for 2024.

• R&D investment ratio has remained above industry average for the past decade.

Portfolio highlights and pipeline

• Commercial portfolio serves nine patient populations with differentiated products in immunology and neurology.

• BIMZELX® (bimekizumab) achieved five major approvals in two months, with strong U.S. commercial coverage and access.

• RYSTIGGO® and ZILBRYSQ® offer a unique, differentiated gMG portfolio, with launches in over 20 countries.

• EVENITY® has reached over 725,000 high-risk fracture patients globally since launch.

• FINTEPLA® is approved for Dravet Syndrome and Lennox-Gastaut Syndrome in multiple regions, with broad patient access.